C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Sells 8,610 Shares of AbbVie Inc. $ABBV

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors lowered its position in AbbVie Inc. (NYSE:ABBV) by 29.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 20,322 shares of the company’s stock after selling 8,610 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors’ holdings in AbbVie were worth $4,643,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Evolution Wealth Management Inc. purchased a new position in AbbVie during the 2nd quarter worth $26,000. Chelsea Counsel Co. purchased a new stake in AbbVie in the third quarter valued at about $26,000. Westend Capital Management LLC acquired a new stake in AbbVie in the fourth quarter worth about $29,000. Texas Capital Bancshares Inc TX acquired a new stake in AbbVie in the third quarter worth about $31,000. Finally, Caitlin John LLC purchased a new stake in shares of AbbVie during the third quarter worth about $33,000. Institutional investors own 70.23% of the company’s stock.

Insiders Place Their Bets

In other news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. The trade was a 66.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. The trade was a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.25% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Royal Bank Of Canada began coverage on shares of AbbVie in a report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price objective on the stock. Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 28th. BMO Capital Markets reaffirmed an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. Finally, Evercore dropped their price objective on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a report on Wednesday, February 4th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and an average price target of $253.15.

AbbVie Stock Down 0.0%

Shares of NYSE ABBV opened at $208.79 on Friday. The business’s 50 day moving average price is $221.58 and its 200 day moving average price is $224.41. The firm has a market cap of $369.17 billion, a P/E ratio of 88.47, a P/E/G ratio of 0.73 and a beta of 0.38. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. During the same period last year, the firm posted $2.16 EPS. AbbVie’s revenue for the quarter was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is 293.22%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.